(London AFP = Yonhap News) The European Union (EU) executive committee officially approved the conditional sale of a novel coronavirus infection (Corona 19) vaccine jointly developed by multinational pharmaceutical company AstraZeneca and Oxford University in the UK on the 29th (local time). did. This vaccine is the third Corona 19 vaccine approved by the EU after the vaccine developed by Pfizer, Bioentech and Modena. The photo was taken last November of AstraZeneca and Oxford Corona 19 vaccine, syringe, and company logo. [email protected]
(Beijing = Yonhap News) Correspondent Jin-Bang Kim = The United States, Europe, and China are competing for a vaccine against the novel coronavirus infection (Corona 19). He criticized the official approval of the co-developed COVID-19 vaccine as a political decision.
The state-run Global Times commented on the EU’s conditional AstraZeneca vaccine approval in a comment on the 31st. It was not taken into account.”
The Global Times said, “The EU places great importance on vaccines because it is difficult to thoroughly control COVID-19, and we will continue to use the vaccine. In particular, even in the situation where the threat to the strain of COVID-19 is increasing, the EU urgently requires vaccination. “The reason to promote it” he emphasized.
“AstraZeneca’s vaccine or Pfizer’s vaccine has never been used on a large scale to prevent infectious diseases, and its safety for use on a large scale has not been confirmed. Cases occurred in the elderly and elderly patients in nursing homes,” he explained.
“It is very surprising that the EU approved the vaccine so quickly,” the expert added.
Shanghai vaccine expert Taorina said, “The EU’s hasty appearance in the vaccination race is because delays in vaccine supply could disrupt vaccination campaigns.” “We aim to vaccinate against the disease, but currently only 2% of the population is vaccinated.
Unauthorized reproduction-redistribution prohibited>
2021/01/31 10:58 sent